PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...

Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. This is an ASCO Meeting Abstract from the 2025 ...

Update (Oct. 1, 00:30 UTC): This article has been updated to include comments from DNA Fund co-founder Chris Miglino. Predictive Oncology (POAI), a biotechnology company specializing in AI-driven ...

Researchers in Japan have developed a predictive model that could improve treatment decisions for advanced pancreatic cancer patients. By combining tumor marker readings with patients' genetic ...

Predictive Oncology, Inc. (NASDAQ:POAI) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...

There is a vast array of predictive analytics tools, but not all are created equal. Software differs widely in terms of capability and usability — not all solutions can address all types of advanced ...

Predictive analytics has become one of the most practical technologies shaping modern business strategy. While it is often ...